Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The European Society of Cardiology

General discussion

The first 150 words of the full text of this article appear below.

Antman: Before proceeding to the general discussion and the questions from the audience, it is worth remembering that it is some 50 years since the last oral anticoagulant, warfarin, was developed. However, at this symposium we have heard exciting information on what could be considered a breakthrough in our therapeutic armamentarium, ximelagatran, the first oral agent in the new class of direct thrombin inhibitors.

Verheugt: The first question from our audience is directed to Dr Antman. You described the phenomenon of rebound activation of the coagulation system when unfractionated heparin or low-molecular-weight heparin (LMWH) therapy is stopped. Could ximelagatran be a good drug to use to provide anticoagulation cover when heparin or LMWHs are stopped?

Antman: Rebound activation after initially successful anticoagulation is a persistent problem in the management of patients with acute coronary syndromes. Many clinicians have come up with a variety of hypotheses to explain . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?